Table 2.
Percentage inhibition of cancer cell proliferation and IC50 values.
| Sample | Cell type | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Colo 205 | Y79 | K562 | MCF | MDA-MB | ||||||
| % inhibition | IC50 | % inhibition | IC50 | % inhibition | IC50 | % inhibition | IC50 | % inhibition | IC50 | |
| NafE (200 μg/mL) |
72.01 ± 9.40 | 24.56 ± 6.63*** | 81.82 ± 2.11 | 55.87 ± 7.19** | 61.82 ± 9.60 | 53.63 ± 6.84** | 54.24 ± 5.39 | 184.36 ± 5.39* | 67.80 ± 0.96 | 50.97 ± 3.10** |
| NafEEa (200 μg/mL) |
70.67 ± 5.30 | 25.79 ± 2.69*** | 68.06 ± 2.02 | 59.50 ± 3.41** | 58.48 ± 5.20 | 98.02 ± 7.47* | 46.57 ± 0.64 | 214.73 ± 0.64* | 52.65 ± 2.02 | 100.81 ± 0.50* |
| Doxorubicin (10 μg/mL) |
92.33 ± 0.45 | 0.39 ± 0.03 | 89.42 ± 2.02 | 0.32 ± 0.10 | 89.42 ± 2.02 | 0.36 ± 0.02 | 92.33 ± 0.45 | 0.36 ± 0.09 | 90.65 ± 2.41 | 0.45 ± 0.11 |
| DMSO 2% (Solvent Cntl) |
3.71 ± 0.56 | — | 3.73 ± 1.53 | — | 3.76 ± 1.00 | — | 4.44 ± 1.70 | — | 4.02 ± 1.17 | — |
Values were the means of four replicates ± standard deviation (SD). Significant P values (***P < 0.001, **P < 0.01, and *P < 0.05) were obtained by Student's t-test analysis. Composite treatments were compared using one-way analysis of variances (ANOVA) and probability values were found to be equal to or less than 0.05 for all the four cell lines.